Check patentability & draft patents in minutes with Patsnap Eureka AI!

Product for predicting treatment sensitivity of colorectal cancer to oxaliplatin

A colorectal cancer, oxaliplatin technology, applied in the field of biomedicine, can solve problems such as lack of specificity

Inactive Publication Date: 2021-12-10
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF11 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these molecular markers lack specificity as oxaliplatin resistance-related molecular markers, and have certain limitations in clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Product for predicting treatment sensitivity of colorectal cancer to oxaliplatin
  • Product for predicting treatment sensitivity of colorectal cancer to oxaliplatin
  • Product for predicting treatment sensitivity of colorectal cancer to oxaliplatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1 Differentially expressed genes

[0094] The present invention downloads GSE28702 from the GEO database, and the sample size of the GSE28702 data set is FOLFOX-sensitive group: FOLFOX-resistant group=42:41.

[0095] Using the R package "limma" (version 3.36.5) to perform differential expression analysis on the GSE28702 dataset, 50 differentially expressed genes were obtained, and the screening criteria were: pvalue0.5. The expression levels of the differentially expressed genes FGB, BEX2, and SLC51A involved in the present invention are shown in Table 1, Figure 1-3 As shown, compared with the FOLFOX-resistant group, the expressions of FGB, BEX2, and SLC51A were down-regulated in the FOLFOX-sensitive group.

[0096] Table 1 Differentially expressed genes

[0097] Gene logFC t P.Value Up / Down FGB -0.599 -2.148 0.035 down BEX2 -0.574 -3.540 0.001 down SLC51A -0.528 -2.182 0.032 down

[0098] Example 2 Diagnost...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a product for predicting the treatment sensitivity of colorectal cancer to oxaliplatin. Bioinformatics researches show that FGB, BEX2 and SLC51A as biomarkers can effectively predict the treatment sensitivity of colorectal cancer patients to the oxaliplatin. The invention provides the product for predicting the treatment sensitivity of the colorectal cancer patients to the oxaliplatin. The product has a relatively good market prospect.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a product for predicting the sensitivity of colorectal cancer to oxaliplatin treatment. Background technique [0002] Colorectal cancer (colorectal cancer) is one of the most common malignant tumors of the digestive tract in the world, which seriously threatens human life and health. the third place. The onset of colorectal cancer is hidden and there are no obvious clinical symptoms in the early stage. Although the diagnosis and treatment methods such as early diagnosis, surgical treatment and neoadjuvant therapy of colorectal cancer have been significantly improved, the mortality rate of colorectal cancer is still as high as 33%. The main treatment for early colorectal cancer is surgery, and the 5-year survival rate is about 56% to 61%. However, many patients are already in the middle and advanced stages when they go to a doctor, and they lose the best chance of surgical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574G01N33/68A61K45/00A61P35/00
CPCC12Q1/6886G01N33/57419G01N33/57484G01N33/86G01N33/68A61K45/00A61P35/00C12Q2600/158C12Q2600/106G01N2333/75G01N2333/4704G01N2333/47
Inventor 杨承刚李昭然王丹李雨晨
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com